Log in to search using one of your social media accounts:

 

NovoCure’s cancer therapy effective in late-stage study

(Reuters) – NovoCure (NSDQ:NVCR) said its lead cancer therapy improved survival rate in brain cancer patients in combination with Avastin in a late-stage study, sending its shares up 23% in extended trading. NovoCure’s therapy, Optune, which was evaluated in combination with Roche Holding AG’s cancer drug, reduced the risk of death by 39% in patients, compared with patients treated with Avastin alone, Novocure said in a statement on Friday. Optune is an FDA-approved device for use in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain tumor in which 90% of adult patients die within 24 months after the diagnosis. The portable, non-invasive device uses low-intensity electric fields to slow and even reverse tumor growth and destroy the cancer cells. Optune in combination with Merck &Co Inc’s chemotherapy drug, temozolomide, was approved by the FDA in October to treat adult patients. Novocure, which went public in October, said it plans to present the data from the study at the 20th Annual Society for Neuro-Oncology Meeting in San Antonio, Texas. The company’s shares closed down 1.6 percent at $22.04 on the Nasdaq on Friday. The post NovoCure’s cancer therapy effective in late-stage study appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Clinical Trials NovoCure Source Type: news

Related Links:

Conclusion This is an interesting piece of research that shows how knowledge in one field of medicine can sometimes be applied to another field with surprising results. But it's important to be realistic about the stage of research. This is very much a "proof of concept" study, and tests on cells, tissues and mice don't necessarily translate into a safe and effective treatment for humans. The study has several limitations, but the fact the treatment so far hasn't been tested on humans is the most important. For one thing, Zika virus doesn't naturally infect mice, so researchers had to use a specially engineered v...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Source Type: news
In this report we show that miR-378, a glioblastoma multiforme down regulated miRNA, may enhance the inhibitory effect of curcumin on this cancer growth. Our results indicated that the inhibitory effect of curcumin was enhanced in miR-378-expressing stable U87 cells in vitro and in vivo, compared to control cells. MiR-378 was found to target p-p38 expression, underlying the observed phenotypic changes. Thus, we concluded that miR-378 enhances the response of glioblastoma multiforme to curcumin treatment, by targeting p38. PMID: 28575858 [PubMed - as supplied by publisher]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusions: ATM and TDP1 co-inhibition represents an effective two-pronged approach to chemoradiosensitize CNS tumors. As TDP1 antagonizes Top1cc formation and efficacy of Top1 poisons such as the camptothecin (CPT) cohort of drugs, our findings will improve existing Top1-mediated anti-cancer strategies by enhancing tumor cell killing while reducing clinical doses and patient side-effects. Furthermore, these findings also suggest an alternative avenue in the clinical management of GBM.Citation Format: Matthew Packer, Ali Saleh, Sachin Katyal. Co-inhibition of ATM and TDP1 as a novel chemosensitization strategy against mal...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Therapies Targeting Checkpoints and Mismatch Repair: Poster Presentations - Proffered Abstracts Source Type: research
This study examined (1) the feasibility of recruiting HGG patients to an exercise-based study and performing fitness assessments; (2) exercise counseling and programming preferences; and (3) associations between fitness, physical activity (PA), and quality of life (QOL).MethodsParticipants completed assessments prior to starting Temozolamide chemotherapy with radiation (T1), at 2  months and 8 months. Fitness was measured with an incremental cycling exercise test to volitional exhaustion (VO2peak) and hand grip dynamometry. The Godin leisure time questionnaire measured PA and the functional assessment for cancer ...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Publication date: Available online 29 January 2017 Source:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer Author(s): Teodora Nikolova, Wynand P. Roos, Oliver H. Krämer, Herwig M. Strik, Bernd Kaina Chloroethylating nitrosoureas (CNU), such as lomustine, nimustine, semustine, carmustine and fotemustine are used for the treatment of malignant gliomas, brain metastases of different origin, melanomas and Hodgkin disease. They alkylate the DNA bases and give rise to the formation of monoadducts and subsequently interstrand crosslinks (ICL). ICL are critical cytotoxic DNA lesions that link the DNA strands covalentl...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
a B Abstract Chloroethylating nitrosoureas (CNU), such as lomustine, nimustine, semustine, carmustine and fotemustine are used for the treatment of malignant gliomas, brain metastases of different origin, melanomas and Hodgkin disease. They alkylate the DNA bases and give rise to the formation of monoadducts and subsequently interstrand crosslinks (ICL). ICL are critical cytotoxic DNA lesions that link the DNA strands covalently and block DNA replication and transcription. As a result, S phase progression is inhibited and cells are triggered to undergo apoptosis and necrosis, which both contribute to the effective...
Source: Biochimica et Biophysica Acta - Category: Biochemistry Authors: Tags: Biochim Biophys Acta Source Type: research
For more nearly four decades, our research has focused on one challenge: improving the delivery and efficacy of anti-cancer therapies. Working on the hypothesis that the abnormal tumor microenvironment fuels tumor progression and treatment resistance, we developed an array of novel imaging technologies and animal models as well as mathematical models to unravel the complex biology of tumors. Using these tools, we demonstrated that the blood and lymphatic vasculature, fibroblasts, immune cells and the extracellular matrix associated with tumors are abnormal, which together create a hostile biochemical and physical tumor mic...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Keynote Lectures Source Type: research
Abstract Despite significant advances in the treatment of systemic cancers, progress in the treatment of primary brain tumors has been quite modest. In addition, an increasing proportion of patients with systemic cancers are presenting with brain-only metastases. These observations highlight the critical role that the blood-brain barrier plays in preventing antineoplastic therapies from reaching the central nervous system in therapeutic concentrations. This review describes the anatomy of the blood-brain barrier and currently available methods to quantify the entry of therapeutic compounds into the brain. It also ...
Source: Oncology (Williston Park, N.Y.) - Category: Cancer & Oncology Authors: Tags: Oncology (Williston Park) Source Type: research
CONCLUSIONS:The SAC hydrogel system is an innovative treatment for local cancer therapy that exhibits high penetration and survival benefit. SAC hydrogel is an excellent vehicle for drug delivery in brain cancer, allowing the surgeons have an effect on treatment in the infiltrating part of the tumor, essential for cancer recurrence, disability and death.
Source: Neuro-Oncology - Category: Cancer & Oncology Authors: Tags: EXPERIMENTAL THERAPEUTICS - PRECLINICAL STUDIES (NON-IMMUNOLOGICAL) Source Type: research
We report on our experience with an intraventricular therapy consisting of alternating cycles of liposomal cytarabine and etoposide.PATIENTS AND METHODS:Between 2005 and 2015, 57 patients aged 0.6 to 23 years (median 8 years) with various malignant brain tumors received intraventricular etoposide 0.25mg (
Source: Neuro-Oncology - Category: Cancer & Oncology Authors: Tags: BRAIN METASTASES Source Type: research
More News: Avastin | Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Clinical Trials | Health | Medical Devices | Merck | Neurology | Study | Temodar